{"url_path":"/sec/cero/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1870404/0001213900-26-057753-index.html","accession_number":"0001213900-26-057753","cik":"0001870404","ticker":"CERO","issuer_name":"CERO THERAPEUTICS HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1870404/0001213900-26-057753-index.html","primary_entity_key":"0001870404","primary_entity_name":"CERO THERAPEUTICS HOLDINGS, INC."},"word_count":92,"has_tables":true,"body_markdown":"**Item\n5. Other Information**\n\n \n\nFrom\ntime to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements\n(as each such term is defined in Item 408 of Regulation S-K). None of our directors or “officers,” as defined in Rule 16a-1(f)\nunder the Securities Exchange Act of 1934, adopted, modified or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1\ntrading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter covered by this report."}